Weight loss entails many health benefits that go beyond the scale, and GLP-1s have been shown to alleviate the symptoms of many medical conditions such as diabetes and cardiovascular issues
In March 2024, FDA approved a new indication to reduce MACE in adults with established CV disease and overweight/obesity based on SELECT, marking the first obesity medication with a dedicated CV riskreduction label in this population
M., Orlandi, F., and Tenconi, L
But up to 35% of the time will have more than one
Meanwhile, compounding pharmacies that sell cheaper knockoffs of these products are disrupting the marketplace
If youre experiencing injection site reactions or want help optimizing your GLP-1 routine, our team is here to guide you with clarity and care